Halozyme Therapeutics (NASDAQ:HALO) Upgraded by Leerink Partners to Outperform Rating

Leerink Partners upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a market perform rating to an outperform rating in a research report released on Friday morning, MarketBeat reports. Leerink Partners currently has $110.00 price objective on the biopharmaceutical company’s stock.

HALO has been the subject of a number of other reports. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, UBS Group reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $103.12 on Friday. The stock’s fifty day moving average is $76.48 and its 200 day moving average is $71.47. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $103.30. The firm has a market capitalization of $12.23 billion, a PE ratio of 30.78, a PEG ratio of 0.36 and a beta of 0.85. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 232.11%. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics will post 7.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 72,477 shares of company stock worth $5,102,643 in the last three months. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. Alpine Woods Capital Investors LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $370,000. Pzena Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $317,000. MidFirst Bank purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $27,000. Occidental Asset Management LLC bought a new stake in Halozyme Therapeutics during the second quarter valued at about $250,000. Finally, Deutsche Bank AG bought a new stake in Halozyme Therapeutics during the second quarter valued at about $3,599,000. Institutional investors own 97.79% of the company’s stock.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.